A man in his early 80s presented with transfusion-dependent macrocytic anaemia, steroid-responsive headaches and recurrent inflammatory flares. Broad infectious, autoimmune and haematological investigations were negative, yet symptoms relapsed each time prednisolone was tapered. The coexistence of refractory inflammation, giant cell arteritis-like features and progressive cytopenias prompted targeted sequencing, which uncovered a somatic UBA1 p.Met41Thr mutation and confirmed vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome. Empirical antimicrobials and high-dose steroids provided only brief control. Ruxolitinib followed by subcutaneous azacitidine stabilised inflammatory markers, enabled gradual steroid tapering and reduced hospitalisations although anaemia remained. This case highlights key diagnostic and management principles. First, clinicians should consider VEXAS in older men with overlapping vasculitic and myelodysplastic features. Second, molecular testing should be pursued even when marrow vacuoles are subtle. Thirdly, multidisciplinary care combining steroid-sparing immunomodulators with clonal-directed therapy is essential.
Background/Objectives: Myelodysplastic syndromes (MDS) carry a highly variable prognosis, stratified by the Revised International Prognostic Scoring System (IPSS-R) and the Molecular IPSS (IPSS-M). CEBPA mutations define a favorable-risk subgroup in acute myeloid leukemia (AML), yet their prognostic significance in MDS has not been characterized. Methods: We analyzed 2442 patients from the International Working Group (IWG) 2022 multi-center MDS registry after pre-specified exclusions. Overall survival (OS) and leukemia-free survival (LFS) were compared between CEBPA-mutated (n = 66; 2.7%) and wild-type patients using Kaplan–Meier estimation and Cox proportional hazards regression, adjusting for age, sex, and IPSS-R score; pre-specified subgroup, sensitivity, competing-risk, and mutation subtype analyses were performed. Results:CEBPA-mutated patients had markedly inferior OS (median 17.2 versus 42.2 months; HR 2.05, 95% CI 1.50–2.79; p < 0.001). After IPSS-R adjustment, the hazard ratio remained adverse (HR 1.39, 95% CI 1.00–1.94; p = 0.053), with uniform directionality across all 13 evaluable subgroups and no significant interaction. Co-mutation adjustment for ASXL1 and STAG2 further attenuated the hazard ratio to HR 1.11 (95% CI 0.79–1.57; p = 0.54), suggesting part of the observed signal reflects co-mutation burden rather than an independent CEBPA effect. Competing-risk analysis suggested that the excess mortality is mediated through AML transformation (CEBPA-mutated versus wild-type subdistribution hazard ratio of 1.89, 95% CI 1.20–2.99; p = 0.006) rather than non-transformative MDS mortality (cause-specific HR 0.97; p = 0.890). Truncating mutations drove the adverse signal (HR 2.21; p = 0.023), while basic leucine zipper (bZIP) domain mutations showed no significant effect (HR 1.25; p = 0.470). Conclusions:CEBPA mutations identify a rare MDS subgroup with markedly inferior survival, driven by truncating loss-of-function mutations and associated with leukemic transformation; the AML-derived bZIP-favorable paradigm does not translate to MDS, and CEBPA mutation status merits a prospective study to assess clinical utility for risk stratification.
30 June 2025 in International Journal Of Community Medicine And Public Health
Background: Patient safety (PS) remains a global healthcare concern. Physicians, through their central role, significantly influence PS culture and adverse event prevention. This research evaluates PS knowledge, attitudes, practices, and their determinants among physicians in Lebanese public hospitals. Methods: This study is a secondary data analysis from a survey conducted with healthcare workers in Lebanese public hospitals in 2020-2021. Data were analyzed using descriptive statistics and multivariate linear regression to identify factors associated with PS compliance. Results: The study included 111 physicians (67% men, 33% women; average age 34 years), with 62.2% working in rural areas. Six dimensions of PS knowledge yielded a mean score of 60/100 (SD=19.9). Mean compliance with PS goals was 58.8/100 (SD=10.7). Multivariate linear regression showed higher compliance associated with urban hospital location, alternating work schedules, presence of a PS office, higher PS knowledge scores, and lower frequency of reporting events. Conclusions: Compliance was highest in urban hospitals with university affiliations, though exceptions indicated these factors alone don't guarantee robust PS practices. Physician engagement, institutionalized prioritization of safeguards, and enforced protocols were key determinants of successful implementation. Active monitoring mechanisms targeting physicians may yield significant improvements, as physicians often establish PS standards within hospitals. PS structures and protocols can be enhanced through reformed accreditation processes integrating more PS dimensions. Inter-hospital collaboration creating continued medical education modules for PS training has shown positive outcomes in Lebanon.
Background: High-risk acute promyelocytic leukemia (APL) [white blood cell (WBC) count >10 × 10 9 /L) accounts for 20%–30% of cases with early mortality of 15%–25%. Optimal induction with reduced-intensity all- trans retinoic acid plus arsenic trioxide (ATRA+ATO) versus intensive chemotherapy remains debated. Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (PROSPERO CRD420261293473), we searched PubMed and Cochrane Library (2000–2025). Reduced-intensity: ATRA+ATO with gemtuzumab ozogamicin (GO; 6–9 mg/m 2 ), low-dose idarubicin (one to two doses of 12 mg/m 2 ), or hydroxyurea; intensive: ATRA-based therapy with three or more anthracycline doses. Random-effects meta-analysis used logit transformation and inverse variance weighting. RoB 2 and ROBINS-I were used to assess risk of bias. Results: A total of 17 studies (1,323 patients, 11 on the reduced-intensity arm and 14 on the intensive arm) were included. Complete remission (CR) was 92.3% (95%CI = 85.9–95.9%, I2 = 0%) versus 89.3% (82.6%–93.6%, I2 = 56%, p = 0.35). Early mortality was 8.8% versus 10.4% ( p = 0.62). Event-free survival (EFS) from two randomized controlled trials (RCTs) favored reduced-intensity induction (HR = 0.23, 95%CI= 0.07–0.76, p = 0.015). Relapse was 3.9% versus 5.5% ( p = 0.49). WBC-stratified CR remained stable at 91.6%–92.5% with reduced-intensity induction, while intensive CR declined from 96.0% to 86.6% at WBC ≥30 × 10 9 /L. Conclusions: Reduced-intensity ATRA+ATO-based induction achieves equivalent CR, comparable early mortality, superior EFS (HR = 0.23, p = 0.015), and lower relapse, supporting ATRA+ATO with GO or low-dose anthracycline as the preferred first-line therapy for high-risk APL. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/ , identifier CRD420261293473.
Anti-N-methyl-D-aspartate (NMDA) encephalitis is marked by rapidly evolving and severe neuropsychiatric symptoms that can affect any age. This case illustrates a woman in her early 40s who was admitted with refractory headache, hallucinations and progressive encephalopathy. After imaging failed to detect a neoplasm, a left salpingo-oophorectomy was performed due to high clinical suspicion, which revealed a mature teratoma. Surgery and immunotherapy led to gradual recovery in physical function and improvement in consciousness. This case highlights the importance of aggressive multimodal therapy, thorough tumour evaluation and consideration of surgical exploration in imaging-negative, refractory anti-NMDA receptor encephalitis.
A woman in her early 60s with stage 3A diffuse large B-cell lymphoma developed anaphylaxis to pegfilgrastim after her first cycle of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) chemotherapy, presenting with syncope, severe diarrhoea and persistent hypotension requiring hospitalisation. Three further cycles were given without growth factor support. After cycle four she developed neutropenic fever and received sargramostim (granulocyte-macrophage colony-stimulating factor) under intensive premedication and intensive care monitoring, which she initially tolerated; on the third administration she developed anaphylaxis requiring epinephrine. She completed all six cycles of R-CHOP without growth factor support, using prophylactic antibiotics and close monitoring, achieved complete remission and remains disease-free 41 months after treatment. To our knowledge, this is the second documented case of anaphylaxis to agents from both the granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor classes in one patient, and the first involving pegfilgrastim.